A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)

Completed · Not applicable

Conditions studied: Diabetes, Heart Failure

In brief

The Ahmanson-UCLA Cardiomyopathy Center is conducting a clinical research study that will assess the use of the medication metformin to improve quality of life, exercise capacity, and improved outcomes in heart failure patients with pre-DM or early DM (type II). If the patient participates in this study, the patient will receive the drug metformin for approximately 3 months. During the study the patient will undergo comprehensive testing which includes blood draws and echocardiograms. The patient will also fill out a questionnaire. The patient must be 18 years old to participate.

Key facts

Study ID

NCT01573949

Run by

University of California, Los Angeles

People needed

7

Starts

2011-12-01

Expected to finish

2012-12-01

Last updated by the study team

2020-09-04

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• symptomatic HF of any etiology
• age ≥ 18 years
• fasting blood sugar equal or greater than 100 mg/dL, or pre-DM (HbA1c 5.7 - 6.4%) or early DM (HbA1c ≥ 6.5%)

You may not qualify if…

• current metformin therapy or other anti-diabetic therapy
• previous intolerance to metformin therapy
• renal dysfunction (Cr >1.5 in men or > 1.4 in women or creatinine clearance < 60 ml/minute)
• history of lactic acidosis
• current or planned pregnancy or breast-feeding

Where it is running

• Ahmanson-UCLA Cardiomyopathy Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.